Literature DB >> 19222817

Cognitive deficits after recovery from thrombotic thrombocytopenic purpura.

April S Kennedy1, Qurana F Lewis, James G Scott, Johanna A Kremer Hovinga, Bernhard Lämmle, Deirdra R Terrell, Sara K Vesely, James N George.   

Abstract

BACKGROUND: Patients with apparent complete recovery from thrombotic thrombocytopenic purpura (TTP) often complain of problems with memory, concentration, and fatigue. STUDY DESIGN AND METHODS: Twenty-four patients who were enrolled in the Oklahoma TTP-HUS Registry for their initial episode of TTP, 1995-2006, and who had ADAMTS13 activity of less than 10 percent were evaluated for a broad range of cognitive functions 0.1 to 10.6 years (median, 4.0 years) after their most recent episode. At the time of their evaluation, they had normal physical and Mini-Mental State Examinations and no evidence of TTP.
RESULTS: The patients, as a group, performed significantly worse on 4 of the 11 cognitive domains tested than standardized US data from neurologically normal individuals adjusted for age, sex, and education (p < 0.05). These four domains measured complex attention and concentration skills, information processing speed, rapid language generation, and rote memorization. Twenty-one (88%) patients performed below expectations on at least 1 of the 11 domains. No clear patterns were observed between cognitive test results and patients' characteristics or features of the preceding TTP, including age, occurrence of severe neurologic abnormalities, multiple episodes, and interval from an acute episode.
CONCLUSION: Patients who have recovered from TTP may have persistent cognitive abnormalities. The abnormalities observed in these patients are characteristic of disorders associated with diffuse subcortical microvascular disease. Studies of larger patient groups will be required to confirm these preliminary observations and to determine patient characteristics that may contribute to persistent cognitive abnormalities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222817     DOI: 10.1111/j.1537-2995.2009.02101.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  19 in total

Review 1.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.

Authors:  Bowie Han; Evaren E Page; Lauren M Stewart; Cassandra C Deford; James G Scott; Lauren H Schwartz; Jedidiah J Perdue; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2015-05-28       Impact factor: 10.047

Review 3.  Thrombotic microangiopathies: multimers, metalloprotease, and beyond.

Authors:  Joel Moake
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

4.  Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood Adv       Date:  2017-04-06

5.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

6.  Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.

Authors:  Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Evan M Braunstein; Michael B Streiff; Satish Shanbhag; Alison R Moliterno; C John Sperati; Rebecca F Gottesman; Robert A Brodsky; Thomas S Kickler; Shruti Chaturvedi
Journal:  Blood       Date:  2019-08-20       Impact factor: 22.113

7.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

8.  Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.

Authors:  Shruti Chaturvedi; Hashim Abbas; Keith R McCrae
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

9.  Acquired thrombotic thrombocytopenic purpura in children: a single institution experience.

Authors:  Somasundaram Jayabose; Theodore S Nowicki; Julie Dunbar; Oya Levendoglu-Tugal; Mehmet F Ozkaynak; Claudio Sandoval
Journal:  Indian J Pediatr       Date:  2012-12-21       Impact factor: 1.967

10.  ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.

Authors:  Galit Sarig
Journal:  Rambam Maimonides Med J       Date:  2014-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.